Skip to Main Content

Medical Devices

Animal-origin-free albumin for medical device and tissue applications.

Across organ and tissue preservation, device coatings, and surgical sealants and adhesives, a recombinant, animal-origin-free albumin replaces plasma-derived HSA and the donor variability and adventitious agent risk it carries.

Where our products fit

Where Albumin Fits in Medical Devices

One albumin source can support several device workflows. Choose yours to see how recombinant albumin fits and what it replaces.

Surgical Sealant / Hemostat

Supply defined, animal-origin-free recombinant albumin as the protein matrix in surgical sealants and hemostatic agents.

Overview

Albumin is the protein backbone of several surgical sealants and hemostats (e.g., albumin–glutaraldehyde tissue adhesives), where it crosslinks to form an adherent, flexible seal.

Sealant consistency and biocompatibility depend on a defined, low-variability albumin source. Recombinant human albumin removes the bovine/plasma origin, its lot variability, and its pathogen-risk documentation burden.

Functions

Sealant Protein Matrix

Albumin-based sealants rely on the albumin matrix to crosslink into a cohesive, tissue-adherent seal; matrix consistency governs mechanical performance and biocompatibility.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Commonly replaces
Bovine or plasma-derived albumin in surgical sealants / hemostats.

Organ / Tissue Preservation

Replace plasma-derived HSA in organ-preservation and ex-vivo perfusion solutions with defined, animal-origin-free recombinant albumin.

Overview

Organ-preservation and ex-vivo machine-perfusion solutions (e.g., STEEN Solution for ex-vivo lung perfusion) use human serum albumin at high concentration as the colloid osmotic and stabilizing component that keeps a donor organ viable during evaluation and transport.

Plasma-derived HSA carries lot-to-lot variability, adventitious-agent testing burden, and supply fragility tied to plasma collection — acute risks when a delayed or failed lot can mean a missed transplant window.

A recombinant human albumin with equivalent osmotic and stabilizing behavior removes the plasma dependency while holding performance and security of supply.

Functions

Colloid Osmotic & Tissue Stabilization

Preservation and perfusion solutions rely on albumin as the primary colloid to maintain oncotic pressure and to carry fatty acids and metal ions and buffer oxidative stress, protecting tissue through hypothermic or normothermic perfusion. Consistency and pathogen-risk profile are critical in a clinical preservation window.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Exbumin®

Approved excipient recombinant human serum albumin, supplied as a lyophilized powder for therapeutic formulation, vaccine stabilization, and viral vector processing.

Commonly replaces
Plasma-derived human serum albumin (HSA) in organ-preservation / perfusion solutions.

Device Surface Coating & Lubricity

Use recombinant albumin as a defined surface coating that reduces protein fouling and thrombogenicity and improves lubricity.

Overview

Albumin is widely used to passivate device and biomaterial surfaces: an adsorbed albumin layer reduces nonspecific protein fouling, platelet adhesion, and thrombogenicity, and improves lubricity on catheters, membranes, and sensors.

Coating performance depends on consistent purity and a defined, animal-origin-free source. Recombinant human albumin provides a reproducible, plasma-free coating protein.

Functions

Surface Passivation & Lubricity

Device surfaces in contact with blood or tissue provoke protein adsorption, cell adhesion, and thrombosis. A pre-adsorbed albumin layer passivates the surface and lowers friction; coating consistency depends on a defined albumin source.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Exbumin®

Approved excipient recombinant human serum albumin, supplied as a lyophilized powder for therapeutic formulation, vaccine stabilization, and viral vector processing.

Commonly replaces
Plasma-derived HSA or BSA used as a device-coating protein.

Final Product Stabilization & Storage

Stabilize albumin-containing device solutions and coatings through storage with excipient recombinant albumin.

Overview

Finished preservation solutions, coating formulations, and sealant components must hold performance through storage and distribution.

Albumin contributes to colloidal and protein stability and protects against surface adsorption during storage. Excipient recombinant albumin provides that stabilization with a regulatory-vetted, plasma-free profile.

Functions

Storage Stabilization

Device solutions and formulations lose performance to aggregation and surface adsorption over shelf life; a stabilizing protein preserves colloidal and functional integrity.

Recommendation
Exbumin®

Approved excipient recombinant human serum albumin, supplied as a lyophilized powder for therapeutic formulation, vaccine stabilization, and viral vector processing.

Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Commonly replaces
Plasma-derived HSA used as a stabilizer in device formulations.

One albumin for every device and preservation workflow.

Preservation solutions, device coatings and surgical adhesives all depend on the same raw material: albumin. When that albumin comes from pooled human plasma, it brings risks you have to manage:

  • Donor variability between lots
  • Viral and adventitious agent risk, controlled only by donor screening and processing
  • TSE/BSE exposure that depends on donor screening
  • Added stabilizers, such as those used in pasteurization, that may not belong in your finished device

Our recombinant human albumin is made without blood or animal-derived components, with no preservatives or added stabilizers, and a supply that does not depend on donation. One albumin, one source, one less risk to explain.